The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
Dr. Raman has succeeded Victoria Richon
Evonik invests in start-up to improve patient recovery after open-chest surgery
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
The entire integration and transition of the brands is expected to be completed by March 2022
Subscribe To Our Newsletter & Stay Updated
